AdvisorNet Financial Inc Acquires New Position in AstraZeneca PLC $AZNCF

AdvisorNet Financial Inc bought a new position in AstraZeneca PLC (OTCMKTS:AZNCF) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 11,973 shares of the company’s stock, valued at approximately $2,361,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AZNCF. Seven Mile Advisory bought a new position in AstraZeneca during the fourth quarter valued at $738,000. Town & Country Bank & Trust CO dba First Bankers Trust CO bought a new stake in shares of AstraZeneca in the 1st quarter worth about $1,351,000. L & S Advisors Inc bought a new stake in shares of AstraZeneca in the 4th quarter worth about $14,863,000. Monetary Management Group Inc. bought a new stake in shares of AstraZeneca in the 4th quarter worth about $1,097,000. Finally, Oarsman Capital Inc. purchased a new stake in shares of AstraZeneca during the 4th quarter valued at about $5,027,000. Institutional investors own 40.87% of the company’s stock.

AstraZeneca Price Performance

Shares of OTCMKTS:AZNCF opened at $187.10 on Wednesday. AstraZeneca PLC has a 12 month low of $122.26 and a 12 month high of $195.00. The company has a 50-day moving average price of $187.10 and a 200 day moving average price of $186.15.

About AstraZeneca

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.